Navigation Links
Treatment with NAC is associated with better outcomes for children with liver failure
Date:1/3/2008

A new retrospective study on the effects of N-acetylcysteine (NAC) on children with acute liver failure not caused by acetaminophen poisoning has found that the treatment was associated with a shorter hospital stay, higher incidence of liver recovery, and better survival after transplantation. The study is in the January issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online via Wiley Interscience (http://www.interscience.wiley.com/journal/livertransplantation).

Acute liver failure in children is rare but can be fatal. Acetaminophen poisoning is a common cause, and is treated with NAC, which acts as an antidote, an anti-inflammatory agent and an antioxidant. One small, uncontrolled study suggested that NAC could also help children with non-acetaminophen induced acute liver failure, leading some medical centers to adopt the treatment. Recently, researchers led by Christine Kortsalioudaki of Kings College Hospital in London sought to retrospectively evaluate whether NAC is beneficial for those children.

They examined the medical records of 170 children who came to Kings College Hospital with non-acetaminophen induced acute liver failure between 1989 and 2004. Those treated before 1994 were not treated with NAC, while those who came after 1995 did receive NAC. All the children also received standard care to maintain normal tissue oxygenation and prevent and address complications of acute liver failure.

The children who received NAC spent fewer days in intensive care, and in the hospital overall. 43 percent survived with their native liver, compared to 22 percent of children who did not receive NAC. And death rates while awaiting transplant, after transplant, and after ten years were notably lower in children who had received NAC. Adverse effects were mentioned in just 11 percent of cases and NAC was discontinued in one.

Our data demonstrates that NAC has minor, self-limited adverse effects and can be safely administered to children with non-acetaminophen induced acute liver failure, the authors report. Additionally this study suggests NAC may have a positive effect on the outcome of non-acetaminophen induced acute liver failure, improving the survival with native liver as well as post liver transplant survival.

An accompanying editorial by Mike Leonis and William Balistreri of the Cincinnati Childrens Hospital Medical Center points out that the two groups compared in Kortsalioudakis study were markedly dissimilar in their clinical presentation which could account for some of the differences in outcomes. Also, further stratification of the NAC-treated group into middle and later years showed better outcomes in the latter group which would argue that the improvement was due to non-NAC related effects.

This study does support the idea that intravenous NAC is a well-tolerated and safe medication for pediatric patients with acute liver failure, Leonis and Balistreri write. However, it raises further question as to whether intravenous NAC is beneficial in pediatric patients with non-acetaminophen induced acute liver failure.

They point out that two current randomized-controlled prospective clinical trials are addressing this question. Hopefully with the completion of both of these studies, convincing information will be available to guide clinicians on the true utility of NAC in non-APAP-induced ALF, they conclude.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Thyroid treatment no quick fix for weight loss in children
2. Shorter HCV treatment shows notable success
3. Journal Sleep: A short-term dose of zolpidem is an effective treatment for insomnia
4. Research suggests new treatment suitable for all patients
5. Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
6. Photo: KFC Colonel Original and Look-a-Like Share Eye Treatment Success Story
7. Cost of glaucoma medications may impact treatment
8. Research Offers Promise for Cirrhosis Treatment
9. In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
10. Treatment Advocacy Centers Top 10 Mental Illness Stories You Didnt Read in 2007
11. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... NJ (PRWEB) , ... May 27, 2016 , ... Two ... named as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award ... their workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to ... which we as a society can control and change. , As nearly 795,000 Americans ... 40 seconds within the United States. Plus, with an estimated 129,000 of these people ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Diana Russell suffers from a form of rheumatoid arthritis ... This disease has put her in a wheelchair, and ... to leave her home.  Because of the size and ... wheelchair.  So if there is a family function, the ... to wait for the bus. Photo - ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology: